Revolution Medicines (RVMD) Non-Current Assets (2019 - 2026)

Revolution Medicines has reported Non-Current Assets for 8 years, with the latest figure at $294.9 million in Q2 2026.

• On a quarterly basis, Non-Current Assets rose 16.51% year-over-year to $294.9 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 26.29% increase from a year earlier, with the FY2025 full-year figure at $279.5 million, up 21.16% from the prior year.
• Non-Current Assets was $294.9 million for Q2 2026 at Revolution Medicines, up from $285.8 million in the prior quarter.
• The five-year high for Non-Current Assets was $294.9 million in Q2 2026, with the low at $148.4 million in Q1 2022.
• Average Non-Current Assets over 5 years is $202.3 million, with a median of $183.1 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Non-Current Assets gained 1.24% in 2023, then jumped 49.26% in 2025.
• Over 5 years, Non-Current Assets stood at $151.7 million in 2022, then rose by 20.22% to $182.4 million in 2023, then advanced by 26.45% to $230.7 million in 2024, then grew by 21.16% to $279.5 million in 2025, then rose by 5.53% to $294.9 million in 2026.
• The last three Non-Current Assets figures came in at $294.9 million (Q2 2026), $285.8 million (Q1 2026), and $279.5 million (Q4 2025), per Business Quant data.